AstraZeneca PLC (AZN)vsBP PLC ADR (BP)
AZN
AstraZeneca PLC
$185.78
+0.93%
HEALTHCARE · Cap: $284.63B
BP
BP PLC ADR
$44.79
+2.80%
ENERGY · Cap: $114.71B
Smart Verdict
WallStSmart Research — data-driven comparison
BP PLC ADR generates 219% more annual revenue ($187.64B vs $58.74B). AZN leads profitability with a 17.4% profit margin vs 0.0%. BP appears more attractively valued with a PEG of 0.18. AZN earns a higher WallStSmart Score of 66/100 (B-).
AZN
Strong Buy66
out of 100
Grade: B-
BP
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.8%
Fair Value
$306.07
Current Price
$185.78
$120.29 discount
Margin of Safety
-4001.1%
Fair Value
$0.94
Current Price
$44.79
$43.85 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Growing faster than its price suggests
Large-cap with strong market position
Generating 4.1B in free cash flow
Areas to Watch
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Trading at 13.0x book value
3.6% revenue growth
ROE of 1.7% — below average capital efficiency
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : BP
The strongest argument for BP centers on PEG Ratio, Market Cap, Free Cash Flow. PEG of 0.18 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.
Bear Case : BP
The primary concerns for BP are Price/Book, Revenue Growth, Return on Equity. A P/E of 2239.0x leaves little room for execution misses. Thin 0.0% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN carries more volatility with a beta of 0.23 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
BP generates stronger free cash flow (4.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (66/100 vs 54/100), backed by strong 17.4% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
BP PLC ADR
ENERGY · OIL & GAS INTEGRATED · USA
BP plc participates in the energy business globally. The company is headquartered in London, the United Kingdom.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?